Lectures Arvekap

This excerpt features a discussion among urologists and oncologists at a medical symposium, primarily focusing on prostate cancer treatment. The conversation highlights the increasing importance of personalized approaches in managing the disease, moving away from “one-size-fits-all” treatments. A significant portion of the discussion centers on hormone therapy, specifically the drug triptorelin, examining its effectiveness in achieving and maintaining testosterone suppression and its clinical benefits for patients. The speakers also debate the utility and safety of intermittent androgen deprivation, acknowledging its potential benefits in certain patient populations while raising concerns about its use in metastatic settings and its impact on cardiovascular risk, emphasizing the need for clearer guidelines.